Literature DB >> 8477765

Abnormal pharmacokinetics: the need for monitoring.

A M Horrevorts1, J W Mouton.   

Abstract

Optimal use of a drug depends on rational dosing and subsequent therapeutic drug monitoring for effectiveness and toxicity. Drug monitoring is not relevant for all drugs, but is indicated in the case of drugs which have a narrow therapeutic range or show a large inter-individual variation. If the response is not satisfactory or toxic side effects are observed, the regimen has to be adjusted or another drug used. Methods have been developed to establish rational dosing schedules for the individual patient. In previous methods, the patient's specific data such as age, length, weight and serum creatinine are integrated with population pharmacokinetic parameters for a drug. This approach is subject to an appreciable margin of error, particularly in patients whose physiology is far from normal. Therapeutic drug monitoring via blood level determination makes it possible to evaluate the patient's individual pharmacokinetic parameters on which a rational dosage regimen can be based.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477765     DOI: 10.1007/bf02389880

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Impact of dosage regimens on the efficacy of antibiotics in the immunocompromised host.

Authors:  I A Bakker-Woudenberg; R Roosendaal
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

2.  Gentamicin serum concentrations: pharmacokinetic predictions.

Authors:  J H Hull; F A Sarubbi
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

Review 3.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 4.  Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics.

Authors:  J Prandota
Journal:  Pediatr Infect Dis J       Date:  1987-12       Impact factor: 2.129

5.  Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.

Authors:  A M Horrevorts; J E Degener; G Dzoljic-Danilovic; M F Michel; K F Kerrebijn; O Driessen; J Hermans
Journal:  Chest       Date:  1985-08       Impact factor: 9.410

6.  Influence of age and renal disease on aminoglycoside dosage.

Authors:  T Hallynck; H H Soep; L Dettli
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

7.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

8.  Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.

Authors:  A M Horrevorts; J de Witte; J E Degener; G Dzoljic-Danilovic; W C Hop; O Driessen; M F Michel; K F Kerrebijn
Journal:  Chest       Date:  1987-11       Impact factor: 9.410

9.  Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations.

Authors:  D E Zaske; R J Cipolle; J C Rotschafer; L D Solem; N R Mosier; R G Strate
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

10.  Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.

Authors:  G B Winnie; J A Cooper; J Witson; R G Cowan; D Mayer; M Lepow
Journal:  Pediatr Infect Dis J       Date:  1991-05       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.